Table 1.
Clinical Dose Regimens of Glucagon-Like Peptide-1 Receptor Agonists
| GLP-1 RAs | Abbreviation | Clinical dosage | Explanation of dose-arm |
|---|---|---|---|
| Albiglutide | Albi | Albi30Q2W | 30 mg once biweekly |
| Albi30QW | 30 mg once weekly | ||
| Albi50Q2W | 50 mg once biweekly | ||
| Albi50QM | 50 mg once monthly | ||
| Exenatide | EX | EX5BID | 5 μg twice daily |
| EX10BID | 10 μg twice daily | ||
| EX2QW | 2 mg once weekly | ||
| Liraglutide | LIR | LIR0.6QD | 0.6 mg once daily |
| LIR1.2QD | 1.2 mg once daily | ||
| LIR1.8QD | 1.8 mg once daily | ||
| Taspoglutide | TAS | TAS20Q2W | 20 mg once weekly |
| TAS20QW | 20 mg once biweekly | ||
| TAS30QW | 30 mg once weekly | ||
| Lixisenatide | LIX | LIX20BID | 20 μg twice daily |
| LIX20QD | 20 μg once daily | ||
| LIX30BID | 30 μg twice daily | ||
| LIX30QD | 30 μg once daily | ||
| LY2189265 | LY | LY0.5/1.0QW | 0.5 mg once weekly for 4 weeks, then 1.0 mg once weekly for 12 weeks |
| LY1.0/1.0QW | 1.0 mg once weekly for 16 weeks | ||
| LY1.0/2.0QW | 1.0 mg once weekly for 4 weeks, then 2.0 mg once weekly for 12 weeks |